The ganglioside GD2, well-established as an immunotherapy target in neuroblastoma, may also have promise in EwS, when combined with other agents such as all-trans retinoic acid, EZH2 inhibitor or antibody targeting HGF [332,333,334]. The gene discussed is HGF; the disease is neuroblastoma.